440 related articles for article (PubMed ID: 24968002)
21. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
22. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
23. Cost of human papillomavirus vaccine delivery in a single-age cohort, routine-based vaccination program in Senegal.
Brennan T; Hidle A; Doshi RH; An Q; Loharikar A; Casey R; Badiane O; Ndiaye A; Diallo A; Loko Roka J; Mejia N; Abimbola T
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A77-A84. PubMed ID: 34955325
[TBL] [Abstract][Full Text] [Related]
24. Costs of delivering human papillomavirus vaccination using a one- or two-dose strategy in Tanzania.
Hsiao A; Struckmann V; Stephani V; Mmbando D; Changalucha J; Baisley K; Levin A; Morgan W; Hutubessy R; Watson-Jones D; Whitworth H; Quentin W
Vaccine; 2023 Jan; 41(2):372-379. PubMed ID: 36460537
[TBL] [Abstract][Full Text] [Related]
25. Costs and cost-effectiveness of 9-valent human papillomavirus (HPV) vaccination in two East African countries.
Kiatpongsan S; Kim JJ
PLoS One; 2014; 9(9):e106836. PubMed ID: 25198104
[TBL] [Abstract][Full Text] [Related]
26. Comparative evaluation of the potential impact of rotavirus versus HPV vaccination in GAVI-eligible countries: a preliminary analysis focused on the relative disease burden.
Kim SY; Sweet S; Chang J; Goldie SJ
BMC Infect Dis; 2011 Jun; 11():174. PubMed ID: 21679420
[TBL] [Abstract][Full Text] [Related]
27. Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models.
Jit M; Demarteau N; Elbasha E; Ginsberg G; Kim J; Praditsitthikorn N; Sinanovic E; Hutubessy R
BMC Med; 2011 May; 9():54. PubMed ID: 21569406
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of routine and campaign use of typhoid Vi-conjugate vaccine in Gavi-eligible countries: a modelling study.
Bilcke J; Antillón M; Pieters Z; Kuylen E; Abboud L; Neuzil KM; Pollard AJ; Paltiel AD; Pitzer VE
Lancet Infect Dis; 2019 Jul; 19(7):728-739. PubMed ID: 31130329
[TBL] [Abstract][Full Text] [Related]
29. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique.
Alonso S; Cambaco O; Maússe Y; Matsinhe G; Macete E; Menéndez C; Sicuri E; Sevene E; Munguambe K
BMC Public Health; 2019 Aug; 19(1):1031. PubMed ID: 31370810
[TBL] [Abstract][Full Text] [Related]
30. Is expanding HPV vaccination programs to include school-aged boys likely to be value-for-money: a cost-utility analysis in a country with an existing school-girl program.
Pearson AL; Kvizhinadze G; Wilson N; Smith M; Canfell K; Blakely T
BMC Infect Dis; 2014 Jun; 14():351. PubMed ID: 24965837
[TBL] [Abstract][Full Text] [Related]
31. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries.
Ochalek J; Abbas K; Claxton K; Jit M; Lomas J
BMJ Glob Health; 2020 Oct; 5(10):. PubMed ID: 33082132
[TBL] [Abstract][Full Text] [Related]
32. Cost of human papillomavirus vaccine delivery at district and health facility levels in Zimbabwe: A school-based vaccination program targeting multiple cohorts.
Hidle A; Brennan T; Garon J; An Q; Loharikar A; Marembo J; Manangazira P; Mejia N; Abimbola T
Vaccine; 2022 Mar; 40 Suppl 1(Suppl 1):A67-A76. PubMed ID: 35181152
[TBL] [Abstract][Full Text] [Related]
33. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
34. Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country.
Burger EA; Campos NG; Sy S; Regan C; Kim JJ
Vaccine; 2018 Aug; 36(32 Pt A):4823-4829. PubMed ID: 29807710
[TBL] [Abstract][Full Text] [Related]
35. Knowledge and awareness of HPV vaccine and acceptability to vaccinate in sub-Saharan Africa: a systematic review.
Perlman S; Wamai RG; Bain PA; Welty T; Welty E; Ogembo JG
PLoS One; 2014; 9(3):e90912. PubMed ID: 24618636
[TBL] [Abstract][Full Text] [Related]
36. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries.
Baral R; Levin A; Odero C; Pecenka C; Tabu C; Mwendo E; Bonsu G; Bawa J; Dadzie JF; Charo J; Antwi-Agyei KO; Amponsa-Achianou K; Jalango RE; Mkisi R; Gordon S; Mzengeza T; Morgan W; Muhib F
PLoS One; 2021; 16(1):e0244995. PubMed ID: 33428635
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of introducing universal human papillomavirus vaccination of girls aged 11 years into the National Immunization Program in Brazil.
Novaes HM; de Soárez PC; Silva GA; Ayres A; Itria A; Rama CH; Sartori AM; Clark AD; Resch S
Vaccine; 2015 May; 33 Suppl 1():A135-42. PubMed ID: 25919154
[TBL] [Abstract][Full Text] [Related]
38. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
39. Human papillomavirus vaccine delivery in Mozambique: identification of implementation performance drivers using the Consolidated Framework for Implementation Research (CFIR).
Soi C; Gimbel S; Chilundo B; Muchanga V; Matsinhe L; Sherr K
Implement Sci; 2018 Dec; 13(1):151. PubMed ID: 30545391
[TBL] [Abstract][Full Text] [Related]
40. The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries.
Howard N; Mounier-Jack S; Gallagher KE; Kabakama S; Griffiths UK; Feletto M; LaMontagne DS; Burchett HE; Watson-Jones D
Hum Vaccin Immunother; 2016 Sep; 12(9):2475-7. PubMed ID: 27159786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
